Gain Therapeutics announced that Matthias Alder has departed the company in order to pursue other opportunities. Upon Alder’s departure, the company appointed Gene Mack, the company’s current CFO, as interim CEO, effective June 25. Mack will retain his role as CFO. Khalid Islam, founder and chairman, will bolster management as executive chairman until a permanent CEO is appointed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Gain Therapeutics Launches Public Offering and Warrants Deal
- Gain Therapeutics 7.12M share Spot Secondary priced at $1.35